Injectable, bioresorbable, and synthetic tissue scaffold

Tempo Therapeutics is at the forefront of tissue engineering biotechnology, leveraging its proprietary MAP (Microporous Annealed Particle) technology to create innovative solutions for regenerative medicine. This first-in-class volumetric injectable porous scaffolding is designed to modulate the body’s immune response, promoting a regenerative rather than inflammatory reaction. By utilizing MAP technology, Tempo aims to develop fully synthetic and precision-engineered materials that can effectively evade the typical Foreign Body Response (FBR), leading to accelerated formation of vascularized tissue. Their approach not only addresses significant clinical challenges in soft tissue reconstruction but also enhances tissue strength and restores function, ultimately improving patient outcomes.

The MAP technology platform is versatile and can be combined with various therapeutic modalities, including controlled release systems for small molecules and stem cell therapies, to enhance therapeutic efficacy. Tempo's lead product, TT101, is currently entering clinical development as a treatment for complex wounds, showcasing the potential of MAP technology to rebuild tissue without the need for additional biological factors. By focusing on immune polarization and the physical microenvironment of scaffolds, Tempo Therapeutics is pioneering a new era in medical technology, with aspirations to develop novel therapies across multiple therapeutic areas and improve the lives of patients in need.

United States

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

Tempo Therapeutics

Company Details